246 related articles for article (PubMed ID: 16160142)
1. Comparing antigenicity and immunogenicity of engineered gp120.
Selvarajah S; Puffer B; Pantophlet R; Law M; Doms RW; Burton DR
J Virol; 2005 Oct; 79(19):12148-63. PubMed ID: 16160142
[TBL] [Abstract][Full Text] [Related]
2. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
[TBL] [Abstract][Full Text] [Related]
3. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.
Pantophlet R; Wilson IA; Burton DR
Protein Eng Des Sel; 2004 Oct; 17(10):749-58. PubMed ID: 15542540
[TBL] [Abstract][Full Text] [Related]
4. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.
Ahmed FK; Clark BE; Burton DR; Pantophlet R
Vaccine; 2012 Jan; 30(5):922-30. PubMed ID: 22142583
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
Stamatos NM; Mascola JR; Kalyanaraman VS; Louder MK; Frampton LM; Birx DL; VanCott TC
J Virol; 1998 Dec; 72(12):9656-67. PubMed ID: 9811699
[TBL] [Abstract][Full Text] [Related]
6. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.
Kumar R; Tuen M; Liu J; Nàdas A; Pan R; Kong X; Hioe CE
Vaccine; 2013 Nov; 31(46):5413-21. PubMed ID: 24051158
[TBL] [Abstract][Full Text] [Related]
7. Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.
Narayan KM; Agrawal N; Du SX; Muranaka JE; Bauer K; Leaman DP; Phung P; Limoli K; Chen H; Boenig RI; Wrin T; Zwick MB; Whalen RG
PLoS One; 2013; 8(1):e52732. PubMed ID: 23326351
[TBL] [Abstract][Full Text] [Related]
8. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.
Chen Y; Wilson R; O'Dell S; Guenaga J; Feng Y; Tran K; Chiang CI; Arendt HE; DeStefano J; Mascola JR; Wyatt RT; Li Y
J Immunol; 2016 Nov; 197(10):3982-3998. PubMed ID: 27815444
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice.
Galkin A; Chen Y; Guenaga J; O'Dell S; Acevedo R; Steinhardt JJ; Wang Y; Wilson R; Chiang CI; Doria-Rose N; Grishaev AV; Mascola JR; Li Y
J Immunol; 2020 Mar; 204(6):1543-1561. PubMed ID: 32066595
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies.
Kim YB; Han DP; Cao C; Cho MW
Virology; 2003 Jan; 305(1):124-37. PubMed ID: 12504547
[TBL] [Abstract][Full Text] [Related]
11. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
12. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
[TBL] [Abstract][Full Text] [Related]
13. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
[TBL] [Abstract][Full Text] [Related]
14. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.
Pantophlet R; Ollmann Saphire E; Poignard P; Parren PW; Wilson IA; Burton DR
J Virol; 2003 Jan; 77(1):642-58. PubMed ID: 12477867
[TBL] [Abstract][Full Text] [Related]
15. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
16. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
[TBL] [Abstract][Full Text] [Related]
17. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
Koch M; Pancera M; Kwong PD; Kolchinsky P; Grundner C; Wang L; Hendrickson WA; Sodroski J; Wyatt R
Virology; 2003 Sep; 313(2):387-400. PubMed ID: 12954207
[TBL] [Abstract][Full Text] [Related]
18. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.
Pantophlet R; Wilson IA; Burton DR
J Virol; 2003 May; 77(10):5889-901. PubMed ID: 12719582
[TBL] [Abstract][Full Text] [Related]
19. Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.
Kumar R; Tuen M; Li H; Tse DB; Hioe CE
Vaccine; 2011 Nov; 29(48):9064-74. PubMed ID: 21945958
[TBL] [Abstract][Full Text] [Related]
20. Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140.
Selvarajah S; Puffer BA; Lee FH; Zhu P; Li Y; Wyatt R; Roux KH; Doms RW; Burton DR
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):301-14. PubMed ID: 18284327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]